Metastatic Breast Cancer Clinical Trials

138 recruiting

Metastatic Breast Cancer Trials at a Glance

180 actively recruiting trials for metastatic breast cancer are listed on ClinicalTrialsFinder across 6 cities in 54 countries. The largest study group is Phase 2 with 72 trials, with the heaviest enrollment activity in New York, Boston, and Houston. Lead sponsors running metastatic breast cancer studies include Memorial Sloan Kettering Cancer Center, Shandong Suncadia Medicine Co., Ltd., and UNC Lineberger Comprehensive Cancer Center.

Browse metastatic breast cancer trials by phase

Treatments under study

About Metastatic Breast Cancer Clinical Trials

Looking for clinical trials for Metastatic Breast Cancer? There are currently 138 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Metastatic Breast Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Metastatic Breast Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 180 trials

Recruiting
Phase 3

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

Metastatic Breast Cancer
Hoffmann-La Roche230 enrolled192 locationsNCT05894239
Recruiting
Phase 1Phase 2

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Metastatic Breast CancerEsophageal AdenocarcinomaGastroesophageal Junction Adenocarcinoma+1 more
Boehringer Ingelheim768 enrolled108 locationsNCT06324357
Recruiting
Phase 2

Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)

Metastatic Breast Cancer
Merck Sharp & Dohme LLC120 enrolled41 locationsNCT06428396
Recruiting
Not Applicable

Exercise in Metastatic Breast Cancer: EMBody

Breast CancerIndolent Metastatic Breast Cancer
Indiana University100 enrolled6 locationsNCT05468034
Recruiting
Phase 1Phase 2

Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer

Metastatic Breast CancerHR+/HER2-negative Breast Cancer
SynDevRx, Inc.52 enrolled10 locationsNCT05455619
Recruiting
Phase 3

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

Locally Advanced (Inoperable) or Metastatic Breast Cancer
AstraZeneca895 enrolled283 locationsNCT04862663
Recruiting

A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer

Metastatic Breast CancerLocally Advanced Breast Cancer
Hoffmann-La Roche500 enrolled17 locationsNCT07347600
Recruiting
Phase 1

A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

Advanced Breast CancerMetastatic Breast Cancer (HR+/ HER2-)
Pfizer260 enrolled9 locationsNCT07318805
Recruiting
Phase 1Phase 2

Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer
Washington University School of Medicine152 enrolled3 locationsNCT06374459
Recruiting
Phase 1Phase 2

A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

Metastatic Breast CancerLocally Advanced Breast CancerUnresectable Breast Carcinoma
BioNTech SE380 enrolled39 locationsNCT06827236
Recruiting
Phase 3

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Metastatic Breast Cancer
LeonaBio500 enrolled224 locationsNCT05696626
Recruiting
Phase 3

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

Breast CancerMetastatic Breast CancerER Positive Breast Cancer+1 more
Olema Pharmaceuticals, Inc.1,000 enrolled85 locationsNCT07085767
Recruiting
Phase 2

A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer

Breast CancerMetastatic Breast CancerMetastatic Breast Carcinoma+2 more
Memorial Sloan Kettering Cancer Center46 enrolled8 locationsNCT05534438
Recruiting
Phase 1

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

Metastatic Breast CancerAdvanced Solid TumorAdvanced Breast Cancer
BeOne Medicines399 enrolled63 locationsNCT06120283
Recruiting
Phase 1

Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer

Breast CancerMetastatic Breast CancerAdvanced Breast Cancer
Boundless Bio, Inc.96 enrolled8 locationsNCT07408089
Recruiting
Phase 2

Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies

Breast CancerMetastatic Breast Cancer
UNC Lineberger Comprehensive Cancer Center700 enrolled1 locationNCT07340541
Recruiting
Phase 1

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Metastatic Breast CancerAdvanced Breast CancerMetastatic Lung Cancer+6 more
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)392 enrolled36 locationsNCT06625775
Recruiting
Phase 3

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

Breast CancerBreast Cancer MetastaticMetastatic Breast Cancer+2 more
BriaCell Therapeutics Corporation404 enrolled79 locationsNCT06072612
Recruiting
Phase 1Phase 2

ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer

Breast CancerMetastatic Breast CancerBreast Cancer Female+2 more
Sarah Sammons, MD65 enrolled1 locationNCT07198724
Recruiting
Phase 1

A Study of HLD-0117 in Patients With Metastatic Breast Cancer

Metastatic Breast Cancer
Halda Therapeutics OpCo, Inc.33 enrolled3 locationsNCT07524855